Shares of the company were up 5.2% in extended trading. The spray, sold under the brand name neffy, will be dosed at 1 ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of ARS Pharmaceuticals (NasdaqGM:SPRY) with a Sector ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...

Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $30 price target The firm says ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ARS Pharmaceuticals (SPRY – Research Report) and ...

ARS Pharmaceuticals’ (Nasdaq: SPRY) shares closed up 3.4% at $10.87 yesterday, after the company announced that the US Food ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...

The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 ...

(Reuters) -The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms ...